There's never a dull week on Wall Street. Let's go over some of the news that will shape the week to come.
Dendreon is a biotech that's making waves with the potential for its revolutionary prostate cancer drug. Analysts see another sharp loss at Dendreon. We're still early in that revolution.
3D Systems is leading the way in 3-D printing. This was one of last year's hottest stocks, but it has fallen sharply over the past two weeks, after a bearish report ate into the hoopla over the ability to print out physical products. The good news for 3D Systems is that Wall Street sees profitability more than doubling in Monday's report.
China Digital TV reports on Tuesday. A couple of years ago, this company was on fire. China's migration to digital television was going to be a monstrous opportunity for the Chinese maker of set-top devices that would ease the transitory process. But after peaking shortly following its IPO six years ago, China Digital TV has since shed more than 95% of its value.
CombiMatrix (NASDAQ:CBMX) is a molecular diagnostics lab offering DNA-based testing services to the prenatal, pediatric, and oncology markets. CombiMatrix will step up with its fourth-quarter results on Wednesday morning.
SandRidge Energy (UNKNOWN:SD.DL) trickles in with fresh financials on Thursday. Analysts see the oil and gas producer merely breaking even this quarter, but the real fireworks should come as the company defends itself against recent activist claims suggesting that SandRidge Energy would be better served with new leadership.
Friday is usually quiet on the earnings front, but that won't stop Vanguard Natural Resources (NASDAQOTH:VNRSQ) from reporting. Vanguard specializes in oil and natural gas properties, but investors are largely attracted to the LLC for its hefty 8.8% yield.
Longtime Fool contributor Rick Aristotle Munarriz has no position in any stocks mentioned. The Motley Fool recommends 3D Systems, owns shares of 3D Systems and Dendreon, and has options on 3D Systems. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.